These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 30530606)

  • 1. Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing
    Abodakpi H; Chang KT; Gao S; Sánchez-Díaz AM; Cantón R; Tam VH
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30530606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel framework to compare the effectiveness of β-lactamase inhibitors against extended-spectrum β-lactamase-producing Enterobacteriaceae.
    Abodakpi H; Chang KT; Zhou J; Byerly C; Tam VH
    Clin Microbiol Infect; 2019 Sep; 25(9):1154.e9-1154.e14. PubMed ID: 30664934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.
    Nicasio AM; VanScoy BD; Mendes RE; Castanheira M; Bulik CC; Okusanya OO; Bhavnani SM; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2075-80. PubMed ID: 26787689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model.
    Islam K; Sime FB; Wallis SC; Bauer MJ; Naicker S; Won H; Zowawi HM; Choudhury MA; Shirin T; Habib ZH; Harris PNA; Flora MS; Roberts JA
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0016222. PubMed ID: 35924928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SHV Hyperproduction as a Mechanism for Piperacillin-Tazobactam Resistance in Extended-Spectrum Cephalosporin-Susceptible
    Han MS; Park KS; Jeon JH; Lee JK; Lee JH; Choi EH; Lee SH
    Microb Drug Resist; 2020 Apr; 26(4):334-340. PubMed ID: 31651221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an
    VanScoy BD; Tenero D; Turner S; Livermore DM; McCauley J; Conde H; Bhavnani SM; Rubino CM; Ambrose PG
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
    Bulik CC; Tessier PR; Keel RA; Sutherland CA; Nicolau DP
    Antimicrob Agents Chemother; 2012 Jan; 56(1):544-9. PubMed ID: 22064538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary piperacillin/tazobactam pharmacokinetics in vitro to determine the pharmacodynamic breakpoint for resistant Enterobacteriaceae.
    Gould M; Ginn AN; Marriott D; Norris R; Sandaradura I
    Int J Antimicrob Agents; 2019 Aug; 54(2):240-244. PubMed ID: 31108222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
    Raveh D; Yinnon AM; Broide E; Rudensky B
    Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: report from the ARREST program.
    Ambrose PG; Bhavnani SM; Jones RN
    Antimicrob Agents Chemother; 2003 May; 47(5):1643-6. PubMed ID: 12709334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Piperacillin/tazobactam as an alternative antibiotic therapy to carbapenems in the treatment of urinary tract infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: an in silico pharmacokinetic study.
    Guet-Revillet H; Tomini E; Emirian A; Join-Lambert O; Lécuyer H; Zahar JR; Jullien V
    Int J Antimicrob Agents; 2017 Jan; 49(1):62-66. PubMed ID: 27876276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-MERINO trial: Any role for piperacillin-tazobactam in treating bloodstream infections caused by extended-spectrum beta-lactamase producing Enterobacteriaceae?
    Sfeir MM
    Int J Antimicrob Agents; 2019 May; 53(5):557-558. PubMed ID: 30880227
    [No Abstract]   [Full Text] [Related]  

  • 13. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
    Docobo-Pérez F; López-Cerero L; López-Rojas R; Egea P; Domínguez-Herrera J; Rodríguez-Baño J; Pascual A; Pachón J
    Antimicrob Agents Chemother; 2013 May; 57(5):2109-13. PubMed ID: 23439636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of multi-drug resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolated from clinical specimens at Bugando Medical Centre, Tanzania to Piperacillin-Tazobactam.
    Petro D; Mushi MF; Moremi N; Iddi S; Mirambo M; Seni J; Mshana SE
    Tanzan J Health Res; 2014 Jan; 16(1):54-7. PubMed ID: 26867273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An evaluation of the in vitro activity of piperacillin/tazobactam.
    Daley D; Mulgrave L; Munro R; Neville S; Smith H; Dimech W
    Pathology; 1996 May; 28(2):167-72. PubMed ID: 8743825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Permeability enhancers sensitize β-lactamase-expressing Enterobacteriaceae and Pseudomonas aeruginosa to β-lactamase inhibitors, thereby restoring their β-lactam susceptibility.
    Ferrer-Espada R; Sánchez-Gómez S; Pitts B; Stewart PS; Martínez-de-Tejada G
    Int J Antimicrob Agents; 2020 Jul; 56(1):105986. PubMed ID: 32335279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
    Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
    Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
    Han SB; Jung SW; Bae EY; Lee JW; Lee DG; Chung NG; Jeong DC; Cho B; Kang JH; Kim HK; Park YJ
    Microb Drug Resist; 2015 Apr; 21(2):244-51. PubMed ID: 25398058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a general hospital.
    Kader AA; Kumar A
    Ann Saudi Med; 2005; 25(3):239-42. PubMed ID: 16119526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.